Impactos da glicação no risco cardiovascular em pacientes com diabetes mellitus tipo 2

Objective: To describe the relationship between advanced glycation and the development of cardiovascular diseases in patients with type 2 Diabetes Mellitus (T2DM), emphasizing pathophysiological mechanisms, biomarkers, assessment methods, and prevention and treatment strategies. Methods: This is an integrative literature review conducted using the MEDLINE/PubMed, LILACS, SciELO, Embase, and Scopus databases. Studies published preferably between 2020 and 2025 in Portuguese, English, or Spanish were included. Study selection was performed independently by two reviewers, followed by a descriptive analysis of the evidence. Results/Discussion: The evidence demonstrates that advanced glycation end products (AGEs) promote inflammation, oxidative stress, endothelial dysfunction, and vascular remodeling, primarily through activation of the AGE–RAGE axis, thereby contributing to atherosclerosis and increasing cardiovascular risk. Biomarkers such as Nε-carboxymethyl lysine (CML), methylglyoxal-derived hydroimidazolone-1 (MG-H1), soluble receptor for advanced glycation end products (sRAGE), the hemoglobin glycation index (HGI), and skin autofluorescence have shown potential for cardiovascular risk stratification. However, their clinical application remains limited by the lack of standardized assessment methods and the predominance of observational studies. Final considerations: Advanced glycation is an important mechanism associated with increased cardiovascular risk in patients with T2DM. However, prospective studies and standardized protocols are still needed to validate the clinical application of these biomarkers and to expand their use in the prevention and management of cardiovascular complications.

Authors

Institutions

Publication Details

Journal
Revista Eletrônica Acervo Saúde
Published
2026-11-16
DOI
https://doi.org/10.25248/reas.e25421.2026
Primary Topic
Advanced Glycation End Products research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Impactos da glicação no risco cardiovascular em pacientes com diabetes mellitus tipo 2

Hermínio Maurício da Rocha Sobrinho, Ana Letícia Teixeira Couto, Marcos Pereira Machado
Revista Eletrônica Acervo Saúde
Advanced Glycation End Products research
article

Impactos da glicação no risco cardiovascular em pacientes com diabetes mellitus tipo 2

Hermínio Maurício da Rocha Sobrinho, Ana Letícia Teixeira Couto, Marcos Pereira Machado
article en

Abstract

Objective: To describe the relationship between advanced glycation and the development of cardiovascular diseases in patients with type 2 Diabetes Mellitus (T2DM), emphasizing pathophysiological mechanisms, biomarkers, assessment methods, and prevention and treatment strategies. Methods: This is an integrative literature review conducted using the MEDLINE/PubMed, LILACS, SciELO, Embase, and Scopus databases. Studies published preferably between 2020 and 2025 in Portuguese, English, or Spanish were included. Study selection was performed independently by two reviewers, followed by a descriptive analysis of the evidence. Results/Discussion: The evidence demonstrates that advanced glycation end products (AGEs) promote inflammation, oxidative stress, endothelial dysfunction, and vascular remodeling, primarily through activation of the AGE–RAGE axis, thereby contributing to atherosclerosis and increasing cardiovascular risk. Biomarkers such as Nε-carboxymethyl lysine (CML), methylglyoxal-derived hydroimidazolone-1 (MG-H1), soluble receptor for advanced glycation end products (sRAGE), the hemoglobin glycation index (HGI), and skin autofluorescence have shown potential for cardiovascular risk stratification. However, their clinical application remains limited by the lack of standardized assessment methods and the predominance of observational studies. Final considerations: Advanced glycation is an important mechanism associated with increased cardiovascular risk in patients with T2DM. However, prospective studies and standardized protocols are still needed to validate the clinical application of these biomarkers and to expand their use in the prevention and management of cardiovascular complications.

Revista Eletrônica Acervo SaúdeVol. 26(11)
Pontifícia Universidade Católica de Goiás (BR)
Good health and well-being
Advanced Glycation End Products research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon